BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
February 22 2021 - 7:00AM
Business Wire
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the
“Company”), a clinical-stage biopharmaceutical company developing
novel therapeutics for the treatment of chronic cough and other
hypersensitization-related disorders, today announced that Roberto
Bellini, BELLUS Health's President and Chief Executive Officer,
will participate in two upcoming virtual healthcare investor
conferences.
Presentation Details:
Event: Cowen 41st Annual Health Care Conference
Format: Respiratory/infections panel discussion
Date/Time: Monday, March 1, 2021 at 10:20 a.m. EST
Event: H.C. Wainwright Global Life Sciences Conference
Format: Prerecorded corporate presentation Date/Time:
Available starting on Tuesday, March 9, 2021 at 7:00 a.m. EST
An audio webcast from the H.C. Wainwright event may be accessed
on the Events and Presentations page under the Investors &
Media section of BELLUS Health's website at www.bellushealth.com.
Following the event, an archived webcast will be available on the
Company’s website.
About BELLUS Health (www.bellushealth.com)
BELLUS Health is a clinical-stage biopharmaceutical company
developing novel therapeutics for the treatment of chronic cough
and other hypersensitization-related disorders. The Company's
product candidate, BLU-5937, is being developed for the treatment
of chronic cough and chronic pruritus.
Chronic cough, the lead indication for BLU-5937, is a cough
lasting more than eight weeks and is associated with significant
adverse physical, social and psychosocial effects on health and
quality of life. It is estimated that approximately 26 million
adults in the United States suffer from chronic cough with
approximately 3 million having refractory chronic cough lasting for
more than a year and approximately 6 million having refractory
chronic cough lasting more than 8 weeks and under one year. There
is no specific therapy approved for refractory chronic cough and
current treatment options are limited.
Chronic pruritus, the second indication for BLU-5937, is
commonly known as chronic itch and is an irritating sensation that
leads to scratching and persists for longer than six weeks, which
can be debilitating and can significantly impact quality of life.
It is a hallmark of many inflammatory skin diseases, including
atopic dermatitis (“AD”). It is estimated that AD afflicts
approximately 5% of adults in the United States. Despite currently
available treatments targeting AD, there continues to be a lack of
options targeting the burden of pruritus in AD patients.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210222005269/en/
Danny Matthews Director, Investor Relations and Communications
danny@bellushealth.com
Media: Julia Deutsch Solebury Trout
jdeutsch@soleburytrout.com
BELLUS Health (TSX:BLU)
Historical Stock Chart
From Mar 2024 to Apr 2024
BELLUS Health (TSX:BLU)
Historical Stock Chart
From Apr 2023 to Apr 2024